NDC 64679-630-01 - ADENOSINE
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 64679-630
- Requested NDC
- 64679-630-01
- Package NDCs from labels
- 64679-630-01, 64679-630-07, 64679-630-02, 64679-630-08
- Manufacturer
- WOCKHARDT USA LLC.
- Effective date
- 2012-10-30
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Adenosine Injection, USP FOR RAPID BOLUS INTRAVENOUS USE | WOCKHARDT USA LLC. | 2012-10-30 | HUMAN PRESCRIPTION DRUG LABEL |
| National Council for Prescription Drug Programs indexing - billing unit | National Council for Prescription Drug Programs | 2012-07-24 | Indexing - Billing Unit |
FDA-Initiated Inactive NDC Indexing#
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 64679-630-01 | ADENOSINE | 2 mL in 1 SYRINGE, GLASS | INJECTION | 2 | 2 | |
| 64679-630-02 | ADENOSINE | 4 mL in 1 SYRINGE, GLASS | INJECTION | 4 | 2 | |
| 64679-630-07 | ADENOSINE | 10 in 1 CARTON | INJECTION | 10 | 2 | |
| 64679-630-08 | ADENOSINE | 10 in 1 CARTON | INJECTION | 10 | 2 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 64679-630-01 | ML - Milliliter | 64679-630 | 0c2afb51-29fe-4fd3-9679-177f373d451d | 1 | 2012-07-24 |
| 64679-630-02 | ML - Milliliter | 64679-630 | a3f673fb-08ad-4969-9bd3-1168d7b253cc | 1 | 2012-07-24 |
| 64679-630-07 | ML - Milliliter | 64679-630 | 9a226a59-5fe2-4e82-b54b-fd758fa54421 | 1 | 2012-07-24 |
| 64679-630-08 | ML - Milliliter | 64679-630 | 4894a0be-8cc4-4871-8236-6b3f2ed4a931 | 1 | 2012-07-24 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| ADENOSINE | ACTIVE INGREDIENT | K72T3FS567 | ADENOSINE INJECTION [WOCKHARDT USA LLC.] | 2 | |
| ADENOSINE | ACTIVE MOIETY | K72T3FS567 | ADENOSINE INJECTION [WOCKHARDT USA LLC.] | 2 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | ADENOSINE INJECTION [WOCKHARDT USA LLC.] | 2 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| XYCOS PINK COLLAGENCREAM | ADENOSINE, NIACINAMIDE | NOKSIBCHO cosmetic Co., Ltd. | a378068a-9b5f-f231-e053-2a95a90a413f | 2020-04-17 | Warnings | K72T3FS567 |
| THE SKIN HOUSE ROSE HeavenEmulsion | ADENOSINE, NIACINAMIDE | NOKSIBCHO cosmetic Co., Ltd. | a2c171f7-243a-fb85-e053-2995a90a4d80 | 2020-04-08 | Warnings | K72T3FS567 |
| THE SKIN HOUSE WRINKLE COLLAGEN AMPOULE | ADENOSINE | NOKSIBCHO cosmetic Co., Ltd. | a21ebea1-abc6-c9e8-e053-2995a90a1196 | 2020-04-08 | Warnings | K72T3FS567 |
| 0.9% SODIUM CHLORIDE | 0.9% SODIUM CHLORIDE | HF Acquisition Co LLC, DBA HealthFirst | a2b8220f-e33a-51c3-e053-2995a90a0734 | 2020-04-07 | Warnings, Adverse reactions | 451W47IQ8X |
| 0.9% SODIUM CHLORIDE | 0.9% SODIUM CHLORIDE | HF Acquisition Co LLC, DBA HealthFirst | a2bba76a-08ce-6902-e053-2995a90ab9c9 | 2020-04-07 | Warnings, Adverse reactions | 451W47IQ8X |
| THE SKIN HOUSE Wrinkle SystemCream | ADENOSINE | NOKSIBCHO cosmetic Co., Ltd. | a21fa53d-f7ae-071c-e053-2995a90adbb7 | 2020-03-31 | Warnings | K72T3FS567 |
| THE SKIN HOUSE Wrinkle System Essence | ADENOSINE | NOKSIBCHO cosmetic Co., Ltd. | a2211d4f-4411-18bf-e053-2995a90a4494 | 2020-03-31 | Warnings | K72T3FS567 |
| THE SKIN HOUSE Wrinkle System EyeCream | ADENOSINE | NOKSIBCHO cosmetic Co., Ltd. | a2220aa2-953a-7b63-e053-2a95a90a6382 | 2020-03-31 | Warnings | K72T3FS567 |
| THE SKIN HOUSE Wrinkle Collagen Toner | ADENOSINE | NOKSIBCHO cosmetic Co., Ltd. | a226a209-a32f-d32e-e053-2a95a90ad0b8 | 2020-03-31 | Warnings | K72T3FS567 |
| SFERANGS COLLAGEN RECHARGING | ADENOSINE | NOKSIBCHO cosmetic Co., Ltd. | a2275fe6-ca8f-6ffe-e053-2995a90a2136 | 2020-03-31 | Warnings | K72T3FS567 |
| SFERANGS COLLAGEN SYNERGY AMPOULE | ADENOSINE | NOKSIBCHO cosmetic Co., Ltd. | a22c5134-d8b1-a185-e053-2995a90ae0f0 | 2020-03-31 | Warnings | K72T3FS567 |
| XYCOS PINK COLLAGEN | ADENOSINE, NIACINAMIDE | NOKSIBCHO cosmetic Co., Ltd. | a22c9f95-e3ab-bfd3-e053-2995a90a3c66 | 2020-03-31 | Warnings | K72T3FS567 |
| XYCOS PINK COLLAGEN SERUM | ADENOSINE, NIACINAMIDE | NOKSIBCHO cosmetic Co., Ltd. | a22d3cad-f8e7-7339-e053-2a95a90af8a4 | 2020-03-31 | Warnings | K72T3FS567 |
| XYCOS PINK COLLAGEN TONER | ADENOSINE, NIACINAMIDE | NOKSIBCHO cosmetic Co., Ltd. | a22d5d31-4c3f-651c-e053-2a95a90ae541 | 2020-03-31 | Warnings | K72T3FS567 |
| THE SKIN HOUSE ROSE HEAVEN | ADENOSINE, NIACINAMIDE | NOKSIBCHO cosmetic Co., Ltd. | a21c097c-82ac-3a21-e053-2995a90a63eb | 2020-03-30 | Warnings | K72T3FS567 |
| THE SKIN HOUSE Rose HeavenCream | ADENOSINE, NIACINAMIDE | NOKSIBCHO cosmetic Co., Ltd. | a21ba34c-2d2d-8033-e053-2995a90a1d74 | 2020-03-30 | Warnings | K72T3FS567 |
| THE SKIN HOUSE ROSE HEAVEN SERUM | ADENOSINE, NIACINAMIDE | NOKSIBCHO cosmetic Co., Ltd. | a21c72f8-00ff-0971-e053-2995a90a2f97 | 2020-03-30 | Warnings | K72T3FS567 |
| THE SKIN HOUSE Wrinkle CollagenEmulsion | ADENOSINE | NOKSIBCHO cosmetic Co., Ltd. | a21f1539-0022-3797-e053-2a95a90a5b92 | 2020-03-30 | Warnings | K72T3FS567 |
| Dextrose and Electrolyte No. 48 | SODIUM LACTATE, POTASSIUM CHLORIDE, MAGNESIUM CHLORIDE, MONOBASIC POTASSIUM PHOSPHATE, SODIUM CHLORIDE AND DEXTROSE MONOHYDRATE | Baxter Healthcare Company | b283a454-0c20-4fbf-92d3-dae1f3cd3cad | 2020-02-13 | Warnings, Adverse reactions | 451W47IQ8X |
| Sodium Chloride | SODIUM CHLORIDE | Baxter Healthcare Corporation | fbc01464-8885-4075-af41-911ffec5ae92 | 2020-01-27 | Warnings, Adverse reactions | 451W47IQ8X |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.